Compare Amgen, Inc. (AMGN) vs NRG Energy Inc (NRG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs NRG Energy Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while NRG Energy Inc trades at $140 (market cap $29.63B). The key difference: Amgen, Inc. is far larger — about 6.6× NRG Energy Inc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | NRG | |
|---|---|---|
Market Cap | $196.12B | $29.63B |
Sector | Health | Utilities |
52-Week High | $388.16 | $184.03 |
52-Week Low | $271.18 | $120.65 |
Enterprise Value | $241.41B | $53.46B |
Dividend Yield | 2.77% | 1.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
NRG Energy trades at $140.42, down 0.04% on the day, with a neutral technical signal and bullish moving averages. The stock shows strong analyst support with 64% buy ratings, but faces high valuation with a P/E of 154.31 and modest net income margin of 0.74%. Recent earnings beat expectations in Q3 and Q4 2025, but missed in Q1 2026, with Q2 2026 results pending. Cash flow from operations was $1.91 billion in 2025, though debt levels have risen significantly.
Outlook is mixed: robust revenue growth and strategic initiatives like the smart home segment offer upside, but elevated debt and margin pressures pose risks. The stock's performance hinges on upcoming Q2 earnings and execution on EBITDA guidance of $5.325–$5.825 billion for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
